Notice: This company has been marked as potentially delisted and may not be actively trading. YS Biopharma (YSB) Institutional Ownership Add Compare Share Share Ownership Stock AnalysisHeadlinesOwnershipTrends Institutional Ownership Changes (13F Filings) for YS Biopharma (NASDAQ:YSB)CurrentInstitutional OwnershipPercentage52.64%Number ofInstitutional Buyers(last 12 months)1TotalInstitutional Inflows(last 12 months)$97.19KNumber ofInstitutional Sellers(last 12 months)0 Get YSB Insider Trade Alerts Want to know when executives and insiders are buying or selling YS Biopharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data YSB Institutional Buying and Selling by Quarter Remove Ads YS Biopharma Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/5/2024 Ovata Capital Management Ltd150,000$153K0.1%N/A0.161% 2/14/2024 Superstring Capital Management LP307,920$166K0.1%N/A0.331% 9/21/2023 Barclays PLC108,894$150K0.0%N/A0.423% 8/14/2023 Prelude Capital Management LLC32,200$44K0.0%N/A0.125% 5/16/2023Snow Lake Management LP1,811,942$2.90M1.7%N/A7.037% 5/16/2023 Hhlr Advisors LTD.751,790$1.20M0.0%N/A2.920% 5/15/2023 RTW Investments LP341,090$546K0.0%N/A1.325% 5/11/2023 FIL Ltd2,718,499$4.35M0.0%N/A10.557% 5/10/2023 Valliance Asset Management Ltd1,607,175$2.57M4.6%N/A6.241% (Data available from 1/1/2016 forward)Remove Ads YSB Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of YSB shares? During the previous two years, 9 institutional investors and hedge funds held shares of YS Biopharma. The most heavily invested institutionals were FIL Ltd ($4.35M), Snow Lake Management LP ($2.90M), Valliance Asset Management Ltd ($2.57M), Hhlr Advisors LTD. ($1.20M), RTW Investments LP ($546K), Superstring Capital Management LP ($166K), and Ovata Capital Management Ltd ($153K).Learn more on YSB's institutional investors. What percentage of YS Biopharma stock is owned by institutional investors? 52.64% of YS Biopharma stock is owned by institutional investors. Learn more on YSB's institutional investor holdings. Which institutional investors have been buying YS Biopharma stock? Of the 9 institutional investors that purchased YS Biopharma stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: FIL Ltd ($2.72M), Snow Lake Management LP ($1.81M), Valliance Asset Management Ltd ($1.61M), Hhlr Advisors LTD. ($751.79K), RTW Investments LP ($341.09K), Superstring Capital Management LP ($307.92K), and Ovata Capital Management Ltd ($150K). How much institutional buying is happening at YS Biopharma? Institutional investors have bought a total of 7,829,510 shares in the last 24 months. This purchase volume represents approximately $12.02M in transactions. Related Companies Dyne Therapeutics Institutional Ownership Ocular Therapeutix Institutional Ownership Ardelyx Institutional Ownership Indivior Institutional Ownership Amphastar Pharmaceuticals Institutional Ownership ANI Pharmaceuticals Institutional Ownership Iovance Biotherapeutics Institutional Ownership Evotec Institutional Ownership Calliditas Therapeutics AB (publ) Institutional Ownership Structure Therapeutics Institutional Ownership This page (NASDAQ:YSB) was last updated on 3/12/2025 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredFormer CIA to Trump – Will you Shut down this secret lab?Deep in the sands of New Mexico lies a government lab so secret it makes Area 51 look like a tourist spot… ...Paradigm Press | SponsoredDeFi Coin on Verge of Breakout!We’re Opening the Ultimate Crypto Vault… Don't let this be the missed opportunity you regret for years. Crypto 101 Media | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Victory Could Spark Major Gains for Gold – Don’t Miss Out This "Patriot's Tax Shield" lets you defend your wealth with real, solid gold. Our exclusive, free wealth pr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding YS Biopharma Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share YS Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free YSB Stock Alerts